Metabolic Medicine

Research into incretin biology and the metabolic effects of GLP-1 and GIP receptor agonists.

Our Metabolic Medicine program follows the rapidly evolving science of the incretin hormones GLP-1 and GIP, and the new generation of single, dual, and triple receptor agonists studied for glycemic control and weight regulation. We review published trial data on efficacy, cardiovascular and renal outcomes, and mechanism — from slowed gastric emptying to central appetite signaling.